UCB and AstraZeneca form alliance for the commercialization of Cimzia in Brazil
UCB and AstraZeneca announced that they have entered into a partnership to register and commercialize UCB's PEGylated anti-TNF alpha drug Cimzia® (certolizumab pegol) in Brazil. The drug is to be registered for the treatment of rheumatoid arthritis and Crohn's disease.
Under the agreement, AstraZeneca will register Cimzia® and upon approval will be the exclusive distributor of Cimzia® in Brazil. In partnership with UCB, AstraZeneca will have the right to distribute future new line extensions related to Cimzia®. UCB retains the right to co-promote Cimzia® as well as future line extensions in Brazil. This partnership with AstraZeneca will help UCB commercialize its rich pipeline of products and foster the growth of UCB's affiliate in Brazil.
"This is an important strategic partnership for us, and supports our combined focus on meeting patient needs and developing innovative medicines," said Mark McDade, COO of UCB. "This relationship will ensure that as many Brazilian patients as possible get access to our innovative medicine Cimzia®."
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.